 In this video I am going to talk about 2 billionaire funds that have bought this penny stock and what do we know if there is massive funds, massive institutional investors that are buying a penny stock that to me shows incredible credibility for that stock in terms of the future potential because you have got to think some of these massive billionaire funds have a lot of resources, they have got a lot of research that they can actually apply to when they are doing their own due diligence on a stock right and to me that really gives me an indication to the potential of a stock if institutional investors are investing in that stock. We will go through the information on this video, it is only going to be a short video because I have been working about 18 hours today teaching and doing YouTube videos so it has been a long day, if you appreciate the grind leave a like on the video that will be absolutely appreciated and also subscribe to this channel if you are new, we cover penny stocks and the latest hot penny stocks, make sure you hit the notification bell to get the latest news on any penny stocks that we talk about in this channel, so thanks for all the support that everybody has been giving, let us get right into the information. I have also got to say I am not a financial advisor, I am a business teacher in my daily life but I am by no means an expert on the stock market, let us go into it. So we have got another buyer pharmaceutical company and what are they focused on? They are focused on metabolic and endoscreen disorders, we improve compliance, absorption and more with them with our proprietary drug delivery technologies and they have got a massive product pipeline which is what we like to see with pharmaceutical stocks if they have got a good pipeline of products that they are developing that shows potential and I think that is what maybe these, partly these investors are thinking about these billionaire investors in terms of their product pipeline. So to go through this before we do that I have got to say thanks for all the support on the channel, I am trying to reach to 10,000 subscribers as fast as we can so in any way you can help out to do that that would be fantastic, I will move back into the information just to respect your time. The two big investors that are invested into this penny stock is Vanguard Group and Blackrock, they are buying shares, they are continuing to buy shares and increasing their stake in this particular penny stock. Again as I said that shows to me that they feel that this company has got a lot of potential if they are increasing their shares in this particular stock. So to go through it I am not going to read through all of this but essentially it is a biopharmaceutical company focused on metabolic and endoscene disorders using its proprietary being a key word, why? Because nobody can copy exactly what they are doing, they have got a competitive advantage if they have got patents involved with that. So drug delivery, technologies, liposins, clinical development pipeline includes a range of areas you can see here. So you can see that this stock has got a lot of potential in terms of the fact that it has got a massive product pipeline. So let's move on. So another recent point here is that they have been defending their patents, that shows to me that they don't just believe in the product but they are defending their IP, their intellectual property in terms of their patents for the product. So what it says here from the CEO, we are pleased with the actions and judgments ordered by the PTAB which validates the strength of liposins patent portfolio and that is from the president there of the company. So they are actually defending their patents, people trying to infringe on them and they are obviously defending them which is brilliant to see. Patents are important within biopharmaceutical companies to stop other people copying what they are doing, to stop other companies copying what they are doing and they are defending what they have got there which is important. So just to mention here and highlight again the importance, the fact that they have got a range of products that is in their pipeline, all the different phases, they are all different phases, a couple of them are phase two, a couple of them are phase three. They are in different phases but they have got a good product portfolio that is in the pipeline that is moving through the phases which is potential catalysts as well. And then this is the chairman, president and chief executive officer of the company and it seems to be an individual that is going to drive the company forward. So it says here Patel has more than 20 years of experience of technology and product development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Leipersen in 1997 Patel led drug delivery research and development in this particular area there and he has got an MS in physical pharmacy at the university or Cincinnati and his PhD in Pharmaceuticals from the University of Utah. His experience of expertise includes strategic planning, I talk a lot about strategic direction on this channel and strategic direction is important if he has got a good strategic direction with the company he is going to produce a very healthy company, I talk a lot about business strategy being very important to a business and it is good that he recognises that, it says technology, assessment development, technical management and product research and development, fantastic. Now what is the price at? So the price currently right now is down a little bit after market is $1.95, that is the current price point on this stock. Now the three analysts have a current price offering on this particularly in terms of what their forecast is on that offering of a low of $3, a medium of $3 and a high of $10. So even if it was to hit the lower $3 mark this would still be a significant increase on the current share price. So I think it has got a lot of potential to run up by the looks of this particular analysts but also the fact that two big billionaire funds are investing in this particular penny stock, that tends to say to me that there is credibility. So you have got the billionaire funds, you have got the fact that a lot of the stuff that they are producing is patent protected and they are defending that IP, intellectual property. It has got a total addressable market for the types of products that they are making. It has got a leadership team that is very effective and is going to drive the company forward. But the main highlight of the video is the fact that again institutional investors are getting involved and increasing their position in this stock. So that is why I think that this stock has got a lot of potential. So thanks for watching the video, again I am very tired. Hopefully this was informative or I am making this video short to respect your time. If you appreciate the direct approach of getting right into this information then do leave the video a like. I really appreciate the support on the channel that everybody has been giving and let's continue that road to 10,000 subscribers. And I will see everybody in the next video.